CYTOKINETICS INC

Cytokinetics Inc.’s stock price declined after the FDA extended its review period for the company’s lead drug, Aficamten, used to treat obstructive hypertrophic cardiomyopathy.

Cytokinetics Inc. has seen its stock price drop after the FDA extended the review period for its lead drug, Aficamten, which is designed to treat obstructive hypertrophic cardiomyopathy.

Cytokinetics Inc’s stock price plummeted after the FDA delayed its review of the company’s lead heart drug, Aficamten, causing concerns about the company’s financial position and future prospects.